DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC

Inclusion Criteria: 1. Aged 18 and above, male or female 2. Pathologically diagnosed with advanced or metastatic inoperable non-small cell lung cancer 3. Prior genetic testing \[DNA-NGS\] results show no mutations in EGFR, BRAF, MET, HER2, KRAS, FGFR2/3，no amplifications in MET and HER2 and no fusions in ALK, ROS1, RET, NTRK, NRG1, EGFR, MET, BRAF, FGFR2/3 4. Based on negative driver gene results, received first-line non-targeted therapy with rapid progression or intolerance, with a progression-free survival (PFS) of ≤6 months (regardless of drug exposure time, calculated from the first day of medication) 5. Have retained tumor tissue samples prior to first-line treatment 6. Patients are from medical centers that can ethically affiliate and have accessible clinical follow-up data. Exclusion Criteria: 1. Patients who do not meet any of the necessary inclusion criteria 2. Presence of other pulmonary diseases that require treatment or are severe, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc. 3. Presence of active infections that require systemic treatment 4. History of drug abuse or alcohol abuse, or mental illness, or suspected allergy or intolerance to the study drug or any of its components 5. Any other conditions deemed unsuitable for entry into this study by the investigator.